Cancer vaccine developer restructures after axing lead drug trial

Immune Design's stock price dropped more than 30 percent on the decision, which pushes the prospects of FDA approval several years into the future.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 12, 2018 Category: Pharmaceuticals Authors: Casey Coombs Source Type: news